Wunderlich Securities Maintains Hold Rating on Heartware International

A report from Wunderlich Securities reiterates its Hold rating and $80 price target on Heartware International

. The report states, “…it now looks clear that Heartware's HVAD will not be reviewed by the FDA's Circulatory System Devices Panel meeting in early December. As a result, FDA approval of the HVAD will now almost certainly be delayed beyond the prevailing Street consensus of early 2012. But we expect the delay could be modest, with a panel meeting possible as soon as either January or February. We reiterate our Hold rating, but we believe an over-reaction to this news could result in an attractive buying opportunity for investors”. HTWR closed yesterday at $62.04.